$648 Million is the total value of VR Adviser, LLC's 31 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 51.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TCDA | Buy | Tricida Inc | $94,845,000 | +37.4% | 9,050,064 | +26.9% | 14.64% | +7.6% |
| ACRS | Aclaris Therapeutics Inc | $71,837,000 | +12.8% | 4,563,962 | 0.0% | 11.08% | -11.7% | |
| COGT | Cogent Biosciences Inc | $60,249,000 | +65.4% | 4,038,117 | 0.0% | 9.30% | +29.6% | |
| RLMD | Sell | Relmada Therapeutics Inc | $56,198,000 | +30.4% | 1,518,056 | -33.1% | 8.67% | +2.1% |
| VRDN | Buy | Viridian Therapeutics Inc | $43,693,000 | +103.8% | 2,130,308 | +15.0% | 6.74% | +59.7% |
| GHRS | Buy | GH Research PLCord sh | $38,731,000 | +21.8% | 3,333,154 | +4.6% | 5.98% | -4.6% |
| PLRX | New | Pliant Therapeutics Inc | $22,561,000 | – | 1,080,000 | +100.0% | 3.48% | – |
| MIST | New | Milestone Pharmaceuticals Inc | $22,293,000 | – | 2,425,737 | +100.0% | 3.44% | – |
| TERN | New | Terns Pharmaceuticals Inc | $21,839,000 | – | 3,707,891 | +100.0% | 3.37% | – |
| Marinus Pharmaceuticals Inc | $20,993,000 | +37.4% | 3,156,803 | 0.0% | 3.24% | +7.6% | ||
| GOSS | New | Gossamer Bio Inc | $20,929,000 | – | 1,747,000 | +100.0% | 3.23% | – |
| ANNX | Buy | Annexon Inc | $19,900,000 | +173.7% | 3,220,050 | +67.0% | 3.07% | +114.5% |
| TIL | Sell | Instil Bio Inc | $19,872,000 | -28.3% | 4,105,779 | -31.5% | 3.07% | -43.8% |
| AKUS | Buy | Akouos Inc | $18,932,000 | +51.3% | 2,800,566 | +5.0% | 2.92% | +18.6% |
| New | Dice Therapeutics Inc | $15,514,000 | – | 764,979 | +100.0% | 2.39% | – | |
| AVTE | Buy | Aerovate Therapeutics Inc | $13,827,000 | +49.8% | 833,927 | +41.2% | 2.13% | +17.4% |
| LianBiospons adr | $10,757,000 | -7.4% | 5,378,341 | 0.0% | 1.66% | -27.4% | ||
| FULC | New | Fulcrum Therapeutics Inc | $9,708,000 | – | 1,200,000 | +100.0% | 1.50% | – |
| INZY | Inozyme Pharma Inc | $7,263,000 | -43.8% | 2,709,987 | 0.0% | 1.12% | -56.0% | |
| New | Ventyx Biosciences Inc | $7,259,000 | – | 207,925 | +100.0% | 1.12% | – | |
| RXDX | New | Prometheus Biosciences Inc | $7,179,000 | – | 121,663 | +100.0% | 1.11% | – |
| SVRA | Buy | Savara Inc | $7,060,000 | +12.8% | 4,555,038 | +10.6% | 1.09% | -11.7% |
| PRVB | Provention Bio Inc | $5,034,000 | +12.5% | 1,118,653 | 0.0% | 0.78% | -11.8% | |
| ALT | Altimmune Inc | $4,716,000 | +9.1% | 369,306 | 0.0% | 0.73% | -14.5% | |
| TRVI | Trevi Therapeutics Inc | $4,697,000 | -45.2% | 3,050,022 | 0.0% | 0.72% | -57.0% | |
| LYRA | Lyra Therapeutics Inc | $4,630,000 | -11.3% | 924,170 | 0.0% | 0.71% | -30.5% | |
| IMCR | New | Immunocore Holdings PLCads | $4,441,000 | – | 94,605 | +100.0% | 0.68% | – |
| LIFE | aTyr Pharma Inc | $4,197,000 | +6.0% | 1,398,889 | 0.0% | 0.65% | -16.9% | |
| Rallybio Corp | $3,886,000 | +91.7% | 268,532 | 0.0% | 0.60% | +50.4% | ||
| AFMD | Affimed NV | $2,943,000 | -25.6% | 1,428,571 | 0.0% | 0.45% | -41.7% | |
| CLDX | Sell | Celldex Therapeutics Inc | $2,108,000 | -91.0% | 75,000 | -91.3% | 0.32% | -92.9% |
| XENE | Exit | Xenon Pharmaceuticals Inc | $0 | – | -30,000 | -100.0% | -0.18% | – |
| KDNY | Exit | Chinook Therapeutics Inc | $0 | – | -489,618 | -100.0% | -1.69% | – |
| Exit | Aadi Bioscience Inc | $0 | – | -1,173,518 | -100.0% | -2.85% | – | |
| VTGN | Exit | VistaGen Therapeutics Inc | $0 | – | -20,697,286 | -100.0% | -3.59% | – |
| TVTX | Exit | Travere Therapeutics Inc | $0 | – | -1,711,102 | -100.0% | -8.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.